Penile squamous cell carcinoma (PSCC) is among the rarest genitourinary cancers, especially in high-income countries, nevertheless, it is burdened with poor survival outcomes.1 Among the risk factors associated with PSCC development, human papillomavirus (HPV) infection is the linchpin of the worldwide spread of this tumor.2, 3 Particularly, HPV DNA is identified in almost 50% of penile tumors with more than 80% of such cases being attributable to high-risk HPV-16 genotype infection.4, 5 Adjuvant chemotherapy is the recommended treatment for patients with node-positive PSSC, while radiotherapy (RT) is only proposed for selected cases.6, 7 Some evidence reported better survival outcomes for PSCC patients harboring HPV infection as compared to those who are HPV-negative,8, 9 however the effects that HPV infection has on adjuvant therapies’ outcomes is still unclear.